Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
Journal of Thoracic Oncology(2022)
Abstract
NCT03502850.
MoreTranslated text
Key words
Limertinib,ASK120067,EGFR T790M mutation,Third-generation EGFR-TKI
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined